By introducing next generation sequencing, clinical laboratories can efficiently examine many genes concurrently enabling an assessment of other BC susceptibility genes in related DNA repair pathways or clinical syndromes in addition to well-known BRCA1/2 mutation carriers. The gene discussed is BRCA1; the disease is breast cancer.